[Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society].

[1]  A. Straube,et al.  Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe , 2017, Cephalalgia : an international journal of headache.

[2]  M. de Tommaso,et al.  Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers , 2017, The Journal of Headache and Pain.

[3]  M. Ruiz,et al.  Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year , 2016, The Journal of Headache and Pain.

[4]  S. Aurora,et al.  The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis , 2017, The Journal of Headache and Pain.

[5]  Mark W. Green,et al.  Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache , 2016, Neurology.

[6]  Dirk U. Wulff,et al.  Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting , 2016, Journal of Neural Transmission.

[7]  P. Martelletti,et al.  A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience , 2016, The Journal of Headache and Pain.

[8]  J. Pascual,et al.  Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? , 2015, Cephalalgia : an international journal of headache.

[9]  F. Ahmed,et al.  OnabotulinumtoxinA for chronic migraine: a critical appraisal , 2015, Therapeutics and clinical risk management.

[10]  P. Martínez-Camblor,et al.  Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine , 2015, Cephalalgia : an international journal of headache.

[11]  David W Dodick,et al.  Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  A. Straube,et al.  Correlation of Headache Frequency and Psychosocial Impairment in Migraine: A Cross‐Sectional Study , 2014, Headache.

[13]  M. Brin,et al.  Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine , 2014, European Journal of Neurology.

[14]  R. Lipton,et al.  OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline , 2013, Journal of the Neurological Sciences.

[15]  R. Ohrbach,et al.  The International Classification of Headache Disorders, 3rd edition (beta version) , 2013, Cephalalgia : an international journal of headache.

[16]  H. Diener,et al.  [Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society]. , 2012, Der Nervenarzt.

[17]  S. Aurora,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program , 2011, Headache.

[18]  R. Lipton,et al.  Chronic Migraine: Epidemiology and Disease Burden , 2011, Current pain and headache reports.

[19]  R. Lipton,et al.  Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS) , 2011, Cephalalgia : an international journal of headache.

[20]  J. Couch.  Amitriptyline in the Prophylactic Treatment of Migraine and Chronic Daily Headache , 2011, Headache.

[21]  M. Brin,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program , 2010, Headache.

[22]  R. Lipton,et al.  Global prevalence of chronic migraine: A systematic review , 2010, Cephalalgia : an international journal of headache.

[23]  R. Lipton,et al.  Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  R. Lipton,et al.  Chronic migraine in the population , 2008, Neurology.

[25]  R. Lipton,et al.  Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults , 2008, Cephalalgia : an international journal of headache.

[26]  E. Uzar,et al.  The effect of sodium valproate on chronic daily headache and its subgroups , 2008, The Journal of Headache and Pain.

[27]  H. Diener,et al.  Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study , 2007, Cephalalgia : an international journal of headache.

[28]  R. Lipton,et al.  Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2007, Headache.